Administrador

BRAFV600 mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in glioblastoma. We sought to determine the activity of vemurafenib, a selective inhibitor of BRAFV600, in patients with gliomas that harbor this mutation. Vemurafenib demonstrated evidence of durable antitumor activity in some patients with BRAFV600-mutant gliomas, […]

This study retrospectively evaluated whether tumor expression of PD-L1 could predict the response of EGFR-mutated NSCLC to EGFR TKI therapy in 101 patients. Strong PD-L1 expression significantly decreased the objective response rate compared with weak or negative PD-L1 expression (35.7% vs 63.2% vs 67.3%; P = .002) and shortened progression-free survival (3.8 vs 6.0 vs

This pooled analysis was designed to evaluate the correlation between extent of ALK FISH positivity and efficacy of crizotinib among patients with non–small cell lung cancer. ALK-positivity above 15% was associated with crizotinib response. In clinical trials of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) treated with crizotinib, evaluation of the relationship

This retrospective study looked at the clinical, histologic, and molecular predictors of response to checkpoint inhibitor therapy for patients with metastatic melanoma. Better objective response rates were associated with metachronous metastases, PD-L1 status, CD163+ histiocytes at advancing edges, and NRAS mutations. Metachronous metastases were associated with longer progression-free survival and overall survival. These biomarkers should be

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used to detect specific

Case-control analysis to identify pancreatic cancer predisposition genes; longitudinal analysis of patients with pancreatic cancer for prognosis. The study included 3030 adults diagnosed as having pancreatic cancer and enrolled in a Mayo Clinic registry between October 12, 2000, and March 31, 2016, with last follow-up on June 22, 2017. Reference controls were 123 136 individuals with

The aim of this study was to develop a new risk model for primary myelodysplastic syndromes (MDS) that integrates information on mutations, karyotype, and clinical variables. The study group consisted of 685 molecularly annotated patients. The study group consisted of 685 molecularly annotated patients from MC (357) and NTUH (328). Multivariate analysis of the MC

This phase II randomized study compared cetuximab monotherapy with irinotecan plus cetuximab among patients with resistant KRAS/ NRAS/ BRAF/ PIK3CA wild-type metastatic colorectal cancer. Patients were enrolled in an open-label, multicenter, phase II trial and randomly assigned to cetuximab 400 mg/m2, then 250 mg/m2 cetuximab weekly, with or without irinotecan 180 mg/m2 every 2 weeks. The

In this multi-institutional cohort study, 142 patients with metastatic castration-resistant prostate cancer treated with either taxanes or androgen receptor signaling (ARS) inhibitors were observed for up to 4.3 years. Pretherapy circulating tumor cell status and treatment type were associated with overall survival. Patients with AR-V7–positive circulating tumor cells had superior overall survival with taxanes vs

In this study of 118,187 tumor samples from a de-identified database, including a subset of 2039 samples from a clinically annotated database, the prevalence of PD-L1 amplification was 0.7%. The objective response rate for patients with solid tumors that harbored PD-L1 amplification was 66.7%, with a median progression-free survival of 15.2 months. The results of this